A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure (BLAST-AHF)
A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Studietyp
Studietyp
Inskrivning (Faktisk)
Inskrivning
Fas
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Ciudad Autónoma de Buenos Aires, Argentina
- Research Site
-
Ciudad De Cordoba, Argentina
- Research Site
-
Cordoba, Argentina
- Research Site
-
Coronel Suarez, Argentina
- Research Site
-
Corrientes, Argentina
- Research Site
-
La Plata, Argentina
- Research Site
-
Moron, Argentina
- Research Site
-
Quilmes, Argentina
- Research Site
-
Rosario, Argentina
- Research Site
-
San Martin, Argentina
- Research Site
-
San Miguel de Tucumán, Argentina
- Research Site
-
Santa Fe, Argentina
- Research Site
-
-
-
-
-
Dimitrovgrad, Bulgarien
- Research Site
-
Kazanlak, Bulgarien
- Research Site
-
Pazardzhik, Bulgarien
- Research Site
-
Pleven, Bulgarien
- Research Site
-
Smolyan, Bulgarien
- Research Site
-
Sofia, Bulgarien
- Research Site
-
Sofia, Bulgarien
- Research Sites
-
-
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48202
- Wayne State University
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45267
- University of Cincinnati
-
-
Tennessee
-
Tullahoma, Tennessee, Förenta staterna, 37388
- Tennessee Center for Clinical Trials
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Michael E DeBakey VA Medical Center
-
-
-
-
-
Afula, Israel
- Research Site
-
Ashkelon, Israel
- Research Site
-
Hadera, Israel
- Research Site
-
Haifa, Israel
- Research Site
-
Jerusalem, Israel
- Research Site
-
Nahariya, Israel
- Research Site
-
Nazareth, Israel
- Research Site
-
Safed, Israel
- Research Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Kanada
- Research Site
-
-
Ontario
-
Ottawa, Ontario, Kanada
- Research Site
-
-
-
-
-
Bad Nauheim, Polen
- Research Site
-
Bialystok, Polen
- Research Site
-
Grodzisk Mazowiecki, Polen
- Research Site
-
Klodzko, Polen
- Research Site
-
Kraków, Polen
- Research Site
-
Lublin, Polen
- Research Site
-
Ruda Slaska, Polen
- Research Site
-
Warszawa, Polen
- Research Site
-
Wroclaw, Polen
- Research Site
-
-
-
-
-
Baia Mare, Rumänien
- Research Site
-
Bucharest, Rumänien
- Research Site
-
Cluj-Napoca, Rumänien
- Research Site
-
Craiova, Rumänien
- Research Site
-
Targu Mures, Rumänien
- Research Site
-
-
-
-
-
Moscow, Ryska Federationen
- Research Site
-
Saint Petersburg, Ryska Federationen
- Research Site
-
Saratov, Ryska Federationen
- Research Site
-
-
-
-
-
Bratislava, Slovakien
- Research Site
-
Kocise, Slovakien
- Research Site
-
Martin, Slovakien
- Research Site
-
-
-
-
-
Brno, Tjeckien
- Research Site
-
Hradec Kralove, Tjeckien
- Research Site
-
Olomouc, Tjeckien
- Research Site
-
Prague, Tjeckien
- Research Site
-
Praha, Tjeckien
- Research Site
-
-
-
-
-
Berlin, Tyskland
- Research Site
-
Dortmund, Tyskland
- Research Site
-
Greifswald, Tyskland
- Research Site
-
-
-
-
-
Budapest, Ungern
- Research Site
-
Kaposvar, Ungern
- Research Site
-
Pecs, Ungern
- Research Site
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Men or women aged ≥21 years and ≤ 85 years 1a.Women of non-child-bearing potential
- Able to provide written informed consent
- Pre-existing diagnosis of heart failure and at least 30 days treatment with daily oral loop diuretics
- Systolic blood pressure ≥105 mmHg and ≤ 160 mmHg within 30 minutes of randomization
- Ventricular rate ≤125 bpm. Patients with rate-controlled persistent or permanent atrial fibrillation (aFib) at screening are permitted.
Presence of ADHF defined by:
BNP > 400 pg/mL or NT-proBNP > 1600 pg/mL
- For patients with BMI >30 kg/m2: BNP > 200 pg/mL or NT-proBNP > 800 pg/mL
- For patients with rate-controlled persistent or permanent aFib: BNP > 600 pg/mL or NT-proBNP > 2400 pg/mL
- Congestion on chest radiograph (CXR)
AND at least two (2) of the following:
- Rales by chest auscultation
- Edema ≥ +1 on a 0-3 + scale, indicating indentation of skin with mild digital pressure that requires 10 or more seconds to resolve in any dependent area including extremities or sacral region.
- Elevated jugular venous pressure (≥8 cm H2O)
- Receipt of a IV loop diuretic at a minimum dose 40 mg furosemide (or equivalent loop diuretic) for the treatment of dyspnea due to ADHF at least 1 hour prior to anticipated randomization and the initiation of study medication
- Patient report of dyspnea at rest or upon minimal exertion during screening at least one hour after administration of IV loop diuretic
Exclusion Criteria:
- Women who are pregnant or breast-feeding
Clinical presentation:
- Suspected ACS based on clinical judgment
- Coronary revascularization in the 3 months prior to screening or planned during current admission.
- Temperature >38.5oC
- Clinically significant anemia
- Serum sodium >145 mEq/L (145 mmol/L)
- Current or planned ultrafiltration, paracentesis, hemofiltration or dialysis at time of screening
- Any mechanical ventilation
- CPAP/BiPAP discontinued less than 1 hour prior to randomization
- History of LVAD or IABP within the last year
- Intravenous radiographic contrast agent within 72 hours prior to screening or presence of acute contrast induced nephropathy at the time of screening
- Presence of clinically significant arrhythmia
- Uncertainty of ability to complete follow up
Medications:
- nitroprusside or nesiritide
- Intravenous nitrates
- use of inotropes
- Use of ARBs within 7 days of prior to randomization
- Use of any investigational medication within 30 days
- clinically significant hypersensitivity or allergy to, or intolerance of, angiotensin receptor blockers
Medical history:
- Major surgery within 8 weeks prior to screening
- Stroke within 3 months prior to screening
- eGFR (sMDRD) <20 mL/min/1.73m2 or >75 mL/min/1.73m2 between presentation and randomization
- Post cardiac or renal transplant
- Listed for renal transplant or cardiac transplant with anticipated transplant time to transplant < 6 months
- History of severe left ventricular outlet obstruction (either valvular or sub-valvular), severe mitral valve stenosis or severe aortic regurgitation
- Cardiac valvular abnormality that requires surgical correction
- Complex congenital heart disease
- Hypertrophic or restrictive cardiomyopathy
- significant pulmonary or hepatic disease that could interfere with the evaluation of safety or efficacy of TRV027
- life expectancy of less than 6 months
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Experimentell: TRV027 dose #1
TRV027 dose #1 via continuous IV infusion
|
TRV027 continuous intravenous infusion Dose #1
Andra namn:
|
|
Experimentell: TRV027 dose #2
TRV027 dose #2 via continuous IV infusion
|
TRV027 continuous intravenous infusion Dose #2
Andra namn:
|
|
Experimentell: TRV027 dose #3
TRV027 dose #3 via continuous IV infusion
|
TRV027 continuous intravenous infusion Dose #3
Andra namn:
|
|
Placebo-jämförare: Placebo
Placebo via continuous IV infusion
|
Placebo continuous intravenous infusion
|
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
composite z score
Tidsram: 30 days
|
The primary clinical endpoint is a of the following outcomes: (1) time from randomization to death through day 30, (2) time from randomization to heart failure re-hospitalization through day 30, (3) time from randomization to worsening heart failure through day 5, (4) change in dyspnea VAS score (calculated area under the curve) from baseline through day 5, and (5) length of initial hospital stay (in days) from randomization.
The component outcomes will be combined by deriving an average Z for each patient.
|
30 days
|
Samarbetspartners och utredare
Sponsor
Sponsor
Utredare
Utredare
- Studierektor: David Soergel, MD, Trevena Inc.
Studieavstämningsdatum
Studera stora datum
Studiestart
Studiestart
Primärt slutförande (Faktisk)
Primärt slutförande
Avslutad studie (Faktisk)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
Andra studie-ID-nummer
- CP027.2002
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .